{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:49:34Z","timestamp":1790617774779,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003386"],"award-info":[{"award-number":["82003386"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1805263"],"award-info":[{"award-number":["U1805263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.intimp.2022.109335","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T06:33:56Z","timestamp":1666334036000},"page":"109335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"PA","title":["Radiomic model to predict the expression of PD-1 and overall survival of patients with ovarian cancer"],"prefix":"10.1016","volume":"113","author":[{"given":"Lanmei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyuan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongping","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2022.109335_b0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.intimp.2022.109335_b0010","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2022.109335_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188503","article-title":"Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer","volume":"1875","author":"Zhang","year":"2021","journal-title":"Biochim. Biophys. Acta, Rev. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2022.109335_b0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109335_b0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/1055-9965.EPI-18-1359","article-title":"The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer","volume":"29","author":"Schwede","year":"2020","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.intimp.2022.109335_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102300","article-title":"A systematic review of phase II trials exploring anti-PD-1\/PD-L1 combinations in patients with solid tumors","volume":"101","author":"Martorana","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.intimp.2022.109335_b0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2022.109335_b0040","article-title":"Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk","volume":"11","author":"Wagner","year":"2020","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.intimp.2022.109335_b0045","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109335_b0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.109335_b0055","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109335_b0060","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.3390\/cancers12113403","article-title":"Integrated Multi-Tumor Radio-Genomic Marker of Outcomes in Patients with High Serous Ovarian Carcinoma","volume":"12","author":"Veeraraghavan","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2022.109335_b0065","doi-asserted-by":"crossref","first-page":"419","DOI":"10.21873\/anticanres.15500","article-title":"Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software","volume":"42","author":"Miyata","year":"2022","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2022.109335_b0070","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1148\/rg.2021210037","article-title":"Radiomics in Oncology: A Practical Guide","volume":"41","author":"Shur","year":"2021","journal-title":"Radiographics."},{"issue":"12","key":"10.1016\/j.intimp.2022.109335_b0075","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.3390\/cancers13123077","article-title":"Virtual Biopsy for Diagnosis of Chemotherapy-Associated Liver Injuries and Steatohepatitis: A Combined Radiomic and Clinical Model in Patients with Colorectal Liver Metastases","volume":"13","author":"Costa","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2022.109335_b0080","article-title":"Automated machine learning based on radiomics features predicts H3 K27M mutation in midline gliomas of the brain","author":"Su","year":"2020","journal-title":"Neuro Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109335_b0085","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.apsb.2021.02.007","article-title":"Applying artificial intelligence for cancer immunotherapy","volume":"11","author":"Xu","year":"2021","journal-title":"Acta Pharm. Sin. B."},{"issue":"4","key":"10.1016\/j.intimp.2022.109335_b0090","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nbt.3772","article-title":"Toil enables reproducible, open source, big biomedical data analyses","volume":"35","author":"Vivian","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109335_b0095","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1172\/JCI127046","article-title":"Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome","volume":"129","author":"Fakih","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2022.109335_b0100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinf."},{"issue":"7","key":"10.1016\/j.intimp.2022.109335_b0105","doi-asserted-by":"crossref","first-page":"1902880","DOI":"10.1002\/advs.201902880","article-title":"ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy","volume":"7","author":"Miao","year":"2020","journal-title":"Adv. Sci. (Weinh)."},{"issue":"D1","key":"10.1016\/j.intimp.2022.109335_b0110","doi-asserted-by":"crossref","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","article-title":"TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment","volume":"49","author":"Sun","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2022.109335_b0115","article-title":"Multi-Region Radiomic Analysis Based on Multi-Sequence MRI Can Preoperatively Predict Microvascular Invasion in Hepatocellular Carcinoma","volume":"12","author":"Gao","year":"2022","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2022.109335_b0120","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1007\/s00330-018-5389-z","article-title":"Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months","volume":"28","author":"Rizzo","year":"2018","journal-title":"Eur. Radiol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109335_b0125","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2022.109335_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.777921","article-title":"Prognostic Value of mRNAsi\/Corrected mRNAsi Calculated by the One-Class Logistic Regression Machine-Learning Algorithm in Glioblastoma Within Multiple Datasets","volume":"8","author":"Zhang","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"15","key":"10.1016\/j.intimp.2022.109335_b0135","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.3390\/cancers13153840","article-title":"Future Screening Prospects for Ovarian Cancer","volume":"13","author":"\u017dilovi\u010d","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.intimp.2022.109335_b0140","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ygyno.2021.05.011","article-title":"Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis","volume":"162","author":"Lin","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2022.109335_b0145","doi-asserted-by":"crossref","first-page":"e002873","DOI":"10.1136\/jitc-2021-002873","article-title":"Immunological configuration of ovarian carcinoma: features and impact on disease outcome","volume":"9","author":"Fucikova","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2022.109335_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188361","article-title":"Targeting tumor microenvironment in ovarian cancer: Premise and promise","volume":"1873","author":"Jiang","year":"2020","journal-title":"Biochim. Biophys. Acta, Rev. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2022.109335_b0155","doi-asserted-by":"crossref","first-page":"e003833","DOI":"10.1136\/jitc-2021-003833","article-title":"Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities","volume":"10","author":"Azarianpour","year":"2022","journal-title":"J. ImmunoTher. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2022.109335_b0160","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/neuonc\/noaa177","article-title":"Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics","volume":"23","author":"Choi","year":"2021","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109335_b0165","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/0008-5472.CAN-20-0999","article-title":"Radiomic Detection of EGFR Mutations in NSCLC","volume":"81","author":"Rossi","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109335_b0170","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0499-y","article-title":"Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer","volume":"7","author":"Yeong","year":"2019","journal-title":"J. ImmunoTher. Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2022.109335_b0175","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1097\/JTO.0000000000000550","article-title":"Association of PDCD1 and CTLA-4 Gene Expression with Clinicopathological Factors and Survival in Non-Small-Cell Lung Cancer: Results from a Large and Pooled Microarray Database","volume":"10","author":"Deng","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109335_b0180","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s40265-016-0588-x","article-title":"Cancer Treatment with Anti-PD-1\/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?","volume":"76","author":"Festino","year":"2016","journal-title":"Drugs."},{"key":"10.1016\/j.intimp.2022.109335_b0185","article-title":"Interpretation of radiomics features-A pictorial review","volume":"215","author":"Abbasian Ardakani","year":"2021","journal-title":"Comput. Methods Programs Biomed."},{"issue":"12","key":"10.1016\/j.intimp.2022.109335_b0190","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109335_b0195","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ. Cardiovasc. Qual. Outcomes."},{"issue":"2","key":"10.1016\/j.intimp.2022.109335_b0200","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41571-021-00560-7","article-title":"Predicting cancer outcomes with radiomics and artificial intelligence in radiology","volume":"19","author":"Bera","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922008190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922008190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:43:33Z","timestamp":1761587013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922008190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"alternative-id":["S1567576922008190"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109335","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiomic model to predict the expression of PD-1 and overall survival of patients with ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109335"}}